BioMarin Pharmaceutical Inc
BMRN55.140USD
+0.770+1.42%
Fechamento 09/18, 16:00（ET）Cotações atrasadas em 15 min
10.59BValor de mercado
16.11P/L TTM
Mais detalhes de BioMarin Pharmaceutical Inc Empresa
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Informações da empresa
Código da empresaBMRN
Nome da EmpresaBioMarin Pharmaceutical Inc
Data de listagemJul 23, 1999
CEOMr. Alexander Hardy
Número de funcionários3040
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 23
Endereço770 Lindaro Street
CidadeSAN RAFAEL
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94901
Telefone14155066700
Sitehttps://www.biomarin.com/
Código da empresaBMRN
Data de listagemJul 23, 1999
CEOMr. Alexander Hardy
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
46.81K
+61.08%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
8.83K
+305.05%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
8.83K
+305.05%
Ms. Elizabeth Mckey Anderson
Ms. Elizabeth Mckey Anderson
Independent Director
Independent Director
--
--
Mr. Timothy Walbert
Mr. Timothy Walbert
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+5.85%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
62.99K
-53.04%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
46.81K
+61.08%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+21.80%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-7.36%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+39.97%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Voxzogo
213.75M
29.10%
Vimizim
188.35M
25.64%
Naglazyme
114.29M
15.56%
Palynziq
93.27M
12.70%
Aldurazyme
48.98M
6.67%
Outro
76.01M
10.35%
Por RegiãoUSD
Nome
Receita
Proporção
United States
241.69M
32.90%
Europe
229.58M
31.25%
Rest of the world
126.11M
17.17%
Latin America
88.28M
12.02%
ALDURAZYME net product revenues marked by Sanofi
48.98M
6.67%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Voxzogo
213.75M
29.10%
Vimizim
188.35M
25.64%
Naglazyme
114.29M
15.56%
Palynziq
93.27M
12.70%
Aldurazyme
48.98M
6.67%
Outro
76.01M
10.35%
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.85%
BlackRock Institutional Trust Company, N.A.
9.39%
PRIMECAP Management Company
8.21%
Dodge & Cox
7.87%
Viking Global Investors LP
6.40%
Outro
58.27%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
9.85%
BlackRock Institutional Trust Company, N.A.
9.39%
PRIMECAP Management Company
8.21%
Dodge & Cox
7.87%
Viking Global Investors LP
6.40%
Outro
58.27%
Tipos de investidores
Investidores
Proporção
Investment Advisor
43.86%
Investment Advisor/Hedge Fund
39.63%
Hedge Fund
7.66%
Pension Fund
3.19%
Research Firm
1.70%
Sovereign Wealth Fund
1.23%
Bank and Trust
1.17%
Individual Investor
0.75%
Venture Capital
0.34%
Outro
0.47%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
1333
195.10M
101.61%
-16.01M
2025Q1
1355
191.53M
99.87%
-20.72M
2024Q4
1336
190.53M
99.88%
-17.50M
2024Q3
1308
188.26M
98.81%
-22.17M
2024Q2
1293
192.58M
101.18%
-14.21M
2024Q1
1278
194.24M
102.38%
-11.23M
2023Q4
1294
193.16M
102.42%
-3.22M
2023Q3
1275
188.66M
100.18%
-4.68M
2023Q2
1283
185.80M
98.76%
-8.08M
2023Q1
1274
186.38M
99.36%
-9.64M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
18.92M
9.87%
-369.57K
-1.92%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
18.12M
9.45%
-16.94K
-0.09%
Mar 31, 2025
PRIMECAP Management Company
17.77M
9.27%
-415.89K
-2.29%
Mar 31, 2025
Dodge & Cox
14.96M
7.8%
+209.00K
+1.42%
Mar 31, 2025
Viking Global Investors LP
10.80M
5.63%
+289.51K
+2.75%
Mar 31, 2025
State Street Global Advisors (US)
8.46M
4.41%
-649.18K
-7.12%
Mar 31, 2025
AQR Capital Management, LLC
2.93M
1.53%
+1.64M
+127.94%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.43M
1.79%
+142.47K
+4.33%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
3.57M
1.86%
-49.67K
-1.37%
Dec 31, 2024
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de set
Atualizado em: sáb, 6 de set
Nome
Proporção
First Trust Mid Cap Growth AlphaDEX Fund
0%
First Trust Mid Cap Core Alphadex Fund
0%
Goldman Sachs Equal Weight US Large Cap Equity ETF
0%
AGF US Market Neutral Anti-Beta Fund
0%
iShares S&P Mid-Cap 400 Growth ETF
0%
iShares Russell 1000 Growth ETF
0%
First Trust Lunt US Factor Rotation ETF
0%
SPDR S&P 400 Mid Cap Growth ETF
0%
QRAFT AI-Enhanced US Large Cap ETF
0%
WisdomTree US LargeCap Fund
0%
Ver Mais
First Trust Mid Cap Growth AlphaDEX Fund
Proporção0%
First Trust Mid Cap Core Alphadex Fund
Proporção0%
Goldman Sachs Equal Weight US Large Cap Equity ETF
Proporção0%
AGF US Market Neutral Anti-Beta Fund
Proporção0%
iShares S&P Mid-Cap 400 Growth ETF
Proporção0%
iShares Russell 1000 Growth ETF
Proporção0%
First Trust Lunt US Factor Rotation ETF
Proporção0%
SPDR S&P 400 Mid Cap Growth ETF
Proporção0%
QRAFT AI-Enhanced US Large Cap ETF
Proporção0%
WisdomTree US LargeCap Fund
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
